UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

____________

FORM 10-Q

☒X Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the quarterly period ended ~~December~~March 31, ~~2020~~2021

Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the transition period from to

Commission File Number 001-31668

INTEGRATED BIOPHARMA, INC.

(Exact name of registrant, as specified in its charter)

Delaware	22-2407475
(State or other jurisdiction of	(I.R.S. Employer
incorporation or organization)	Identification No.)

225 Long Ave., Hillside, New Jersey	07205
(Address of principal executive offices)	(Zip Code)

(888) 319-6962

(~~Registrant’s~~Registrant’s telephone number, including Area Code)

Not Applicable

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Exchange Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
None	None	None

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities and Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes __X__ No ____

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

Yes __X__ No ____

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.


Large accelerated filer ☐		Accelerated filer ☐		Non-accelerated filer ☑		Emerging growth company ☐		Smaller reporting company ☑

If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes ____ No __X__

As of ~~February 12,~~May 13, 2021, there were ~~29,691,943~~29,769,943 shares of common stock, $0.002 par value per share, of the registrant outstanding.

INTEGRATED BIOPHARMA, INC. AND SUBSIDIARIES

FORM 10-Q QUARTERLY REPORT

For the Three Months Ended ~~December~~March 31, ~~2020~~2021

INDEX

			Page
	Part I. Financial Information
Item 1.	Condensed Consolidated Statements of Income for the ~~Three~~three and ~~Six Months Ended December~~nine months ended March 31, ~~2020~~2021 and ~~2019~~2020 (unaudited)	2
	Condensed Consolidated Balance Sheets as of ~~December~~March 31, ~~2020~~2021 and June 30, 2020 (unaudited)	3
	Condensed Consolidated Statement of Stockholders’ Equity for the ~~Six Months Ended December~~nine months ended March 31, ~~2020~~2021 and ~~2019~~2020 (unaudited)	4
	Condensed Consolidated Statements of Cash Flows for the ~~Six Months Ended December~~nine months ended March 31, ~~2020~~2021 and ~~2019~~2020 (unaudited)	5
	Notes to the Condensed Consolidated Financial Statements (unaudited)	6

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	17

Item 3.	Quantitative and Qualitative Disclosures about Market Risk	24

Item 4.	Controls and Procedures	2425

	Part II. Other Information

Item 1.	Legal Proceedings	25

Item 1A.	Risk Factors	25

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	25

Item 3.	Defaults Upon Senior Securities	2526

Item 4.	Mine Safety Disclosure	2526

Item 5.	Other Information	26

Item 6.	Exhibits	26
	Other
Signatures		27

Cautionary Statement Regarding Forward-Looking Statements

Certain statements in this Quarterly Report on Form 10-Q may constitute “forward-looking” statements as defined in Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the Private Securities Litigation Reform Act of 1995 (the “PSLRA”) or in releases made by the Securities and Exchange Commission (“SEC”), all as may be amended from time to time. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause the actual results, performance or achievements of Integrated BioPharma, Inc. and its subsidiaries (collectively, the “Company”) or industry results, to differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, changes in general economic and business conditions; the outbreak and continued spread of COVID-19; loss of market share through competition; introduction of competing products by other companies; the timing of regulatory approval and the introduction of new products by the Company; changes in industry capacity; pressure on prices from competition or from purchasers of the Company's products; regulatory changes in the pharmaceutical manufacturing industry and nutraceutical industry; regulatory obstacles to the introduction of new technologies or products that are important to the Company; availability of qualified personnel; the loss of any significant customers or suppliers; and other factors both referenced and not referenced in the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2020 (“Form 10-K”), as filed with the SEC. Statements that are not historical fact are forward-looking statements. Forward-looking statements can be identified by, among other things, the use of forward-looking language, such as the words, “plan”, “believe”, “expect”, “anticipate”, “intend”, “estimate”, “project”, “may”, “will”, “would”, “could”, “should”, “seeks”, or “scheduled to”, or other similar words, or the negative of these terms or other variations of these terms or comparable language, or by discussion of strategy or intentions. These cautionary statements are being made pursuant to the Securities Act, the Exchange Act and the PSLRA with the intention of obtaining the benefits of the “safe harbor” provisions of such laws. The Company cautions investors that any forward-looking statements made by the Company are not guarantees or indicative of future performance. Important assumptions and other important factors that could cause actual results to differ materially from those forward-looking statements with respect to the Company, include, but are not limited to, the risks and uncertainties affecting its businesses described in Item 1A of the Company’s Form 10-K and in other securities filings by the Company. Although the Company believes that its plans, intentions and expectations reflected in or suggested by such forward-looking statements are reasonable, actual results could differ materially from a projection or assumption in any of the forward-looking statements. The Company’s future financial condition and results of operations, as well as any forward-looking statements, are subject to change and inherent risks and uncertainties. The forward-looking statements contained in this Quarterly Report on Form 10-Q are made only as of the date hereof and the Company does not have or undertake any obligation to update or revise any forward-looking statements whether as a result of new information, subsequent events or otherwise, unless otherwise required by law.

-1-

ITEM 1. FINANCIAL STATEMENTS

INTEGRATED BIOPHARMA, INC. AND SUBSIDIARIES	INTEGRATED BIOPHARMA, INC. AND SUBSIDIARIES													INTEGRATED BIOPHARMA, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF INCOME	CONDENSED CONSOLIDATED STATEMENTS OF INCOME													CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(in thousands, except for share and per share amounts)	(in thousands, except for share and per share amounts)													*(in thousands, except for share and per share amounts)*
(Unaudited)	(Unaudited)													(Unaudited)

		Three months ended						Six months ended							Three months ended						Nine months ended
		December 31,						December 31,							March 31,						March 31,
		2020			2019			2020			2019				2021			2020			2021			2020

Sales, net		$	14,257		$	14,197		$	29,429		$	25,603			$	17,072		$	13,631		$	46,501		$	39,234

Cost of sales			12,083			12,171			24,882			22,178				14,411			11,779			39,293			33,957

Gross profit			2,174			2,026			4,547			3,425				2,661			1,852			7,208			5,277

Selling and administrative expenses			930			821			1,794			1,744				942			892			2,736			2,636

Operating income			1,244			1,205			2,753			1,681				1,719			960			4,472			2,641

Other income (expense), net
Interest expense			(79	)		(109	)		(155	)		(233	)			(58	)		(96	)		(213	)		(329	)
Realized gain on sale of investment in iBio Stock			-			-			56			-				-			49			56			49
Unrealized loss on investments			(44	)		(31	)		(73	)		(55	)
Unrealized gain (loss) on investments																22			90			(51	)		35
Other income, net			8			6			16			27				23			-			39			27
Other income (expense), net			(115	)		(134	)		(156	)		(261	)			(13	)		43			(169	)		(218	)

Income before income taxes			1,129			1,071			2,597			1,420				1,706			1,003			4,303			2,423

Provision for income taxes			(95	)		112			332			149				465			67			797			216

Net income		$	1,224		$	959		$	2,265		$	1,271			$	1,241		$	936		$	3,506		$	2,207

Basic earnings per common share		$	0.04		$	0.03		$	0.08		$	0.04			$	0.04		$	0.03		$	0.12		$	0.07

Diluted earnings per common share		$	0.04		$	0.03		$	0.07		$	0.04			$	0.04		$	0.03		$	0.11		$	0.07

Weighted average common shares outstanding - basic
29,658,661 29,565,943 29,652,302 29,565,943
Add: Equivalent shares outstanding
2,440,843 1,025,020 2,314,734 1,042,300
Weighted average common shares outstanding - diluted
32,099,504 30,590,963 31,967,036 30,608,243

~~See accompanying notes to condensed consolidated financial statements.~~

~~-2-~~

INTEGRATED BIOPHARMA, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands, except for share and per share amounts)

(Unaudited)

December 31,

June 30,

2020

2020

Assets

Current Assets:

Cash
$ 43 $ 402
Accounts receivable, net
4,537 5,507
Inventories
13,916 10,101
Other current assets
603 451
Total current assets
19,099 16,461

Property and equipment, net
1,651 1,696
Operating lease right-of-use assets (includes $2,557 and $2,788 with a related party)
2,583 2,824
Deferred tax assets, net
1,857 1,883
Security deposits and other assets
73 80
Total Assets
$ 25,263 $ 22,944

Liabilities and Stockholders' Equity:

Current Liabilities:

Advances under revolving credit facility
$ 3,475 $ 4,046
Accounts payable (includes $64 and $62 due to related party)
6,132 4,358
Accrued expenses and other current liabilities
1,309 1,384
Current portion of long term debt, net
2,856 2,823
Current portion of operating lease liabilities (includes $476 and $467 with a related party)
493 488
Total current liabilities
14,265 13,099

Long term debt, net
470 1,436
Operating lease liabilities (includes $2,086 and $2,327 with a related party)
2,095 2,342
Total liabilities
16,830 16,877

Commitments and Contingencies

Stockholders' Equity :

Common Stock, $0.002 par value; 50,000,000 shares authorized;

29,715,843 and 29,680,843 shares issued and

29,680,943 and 29,645,943 shares outstanding, respectively
59 59
Additional paid-in capital
50,364 50,263
Accumulated deficit
(41,891 ) (44,156 )
Less: Treasury stock, at cost, 34,900 shares
(99 ) (99 )
Total Stockholders' Equity
8,433 6,067
Total Liabilities and Stockholders' Equity
$ 25,263 $ 22,944
Weighted average common shares outstanding - basic
29,709,992 29,565,943 29,671,251 29,565,943
Add: Equivalent shares outstanding
3,153,646 1,319,380 2,774,164 1,113,309
Weighted average common shares outstanding - diluted
32,863,638 30,885,323 32,445,415 30,679,252

See accompanying notes to condensed consolidated financial statements.

~~-3-~~-2-

INTEGRATED BIOPHARMA, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY

FOR THE SIX MONTHS ENDED DECEMBER 31, 2020 AND 2019

(in thousands, except shares)

(Unaudited)

FOR THE SIX MONTHS ENDED DECEMBER 31, 2020:

Common Stock

Additional

Accumulated

Treasury Stock

Total Stockholders'

Shares

Par Value

Paid-in-Capital

Deficit

Shares

Cost

Equity

Balance, July 1, 2020
29,680,843 $ 59 $ 50,263 $ (44,156 ) 34,900 $ (99 ) $ 6,067
Stock compensation expense for employee stock options
- - 8 - - - 8
Net income
- - - 1,041 - - 1,041
Balance, September 30, 2020
29,680,843 59 50,271 (43,115 ) 34,900 (99 ) 7,116
Stock compensation expense for employee stock options
- - 86 - - - 86
Shares issued upon exercise of employee stock options
35,000 - 7 - - - 7
Net income
- - - 1,224 - - 1,224
Balance, December 31, 2020
29,715,843 $ 59 $ 50,364 $ (41,891 ) 34,900 $ (99 ) $ 8,433

FOR THE SIX MONTHS ENDED DECEMBER 31, 2019:

Common Stock

Additional

Accumulated

Treasury Stock

Total Stockholders'

Shares

Par Value

Paid-in-Capital

Deficit

Shares

Cost

Equity

Balance, July 1, 2019
29,600,843 $ 59 $ 50,197 $ (48,264 ) 34,900 $ (99 ) $ 1,893
Stock compensation for employee stock options
- - 15 - - - 15
Net income
- - - 312 - - 312
Balance, September 30, 2019
29,600,843 59 50,212 (47,952 ) 34,900 (99 ) 2,220
Stock compensation expenses for employee stock options
- - 15 - - - 15
Net income
- - - 959 - - 959
Balance, December 31, 2019
29,600,843 $ 59 $ 50,227 $ (46,993 ) 34,900 $ (99 ) $ 3,194

INTEGRATED BIOPHARMA, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands, except for share and per share amounts)

(Unaudited)

March 31,

June 30,

2021

2020

Assets

Current Assets:

Cash
$ 105 $ 402
Accounts receivable, net
6,455 5,507
Inventories
13,422 10,101
Other current assets
544 451
Total current assets
20,526 16,461

Property and equipment, net
1,637 1,696
Operating lease right-of-use assets (includes $2,440 and $2,788 with a related party)
2,460 2,824
Deferred tax assets, net
1,462 1,883
Security deposits and other assets
46 80
Total Assets
$ 26,131 $ 22,944

Liabilities and Stockholders' Equity:

Current Liabilities:

Advances under revolving credit facility
$ 2,516 $ 4,046
Accounts payable (includes $71 and $62 due to related party)
6,594 4,358
Accrued expenses and other current liabilities
1,596 1,384
Current portion of long term debt, net
3,171 2,823
Current portion of operating lease liabilities (includes $480 and $467 with a related party)
495 488
Total current liabilities
14,372 13,099

Long term debt, net
40 1,436
Operating lease liabilities (includes $1,965 and $2,327 with a related party)
1,970 2,342
Total liabilities
16,382 16,877

Commitments and Contingencies

Stockholders' Equity :

Common Stock, $0.002 par value; 50,000,000 shares authorized;

29,782,543 and 29,680,843 shares issued and

29,747,643 and 29,645,943 shares outstanding, respectively
60 59
Additional paid-in capital
50,438 50,263
Accumulated deficit
(40,650 ) (44,156 )
Less: Treasury stock, at cost, 34,900 shares
(99 ) (99 )
Total Stockholders' Equity
9,749 6,067
Total Liabilities and Stockholders' Equity
$ 26,131 $ 22,944

See accompanying notes to condensed consolidated financial statements.

-3-

INTEGRATED BIOPHARMA, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY

FOR THE NINE MONTHS ENDED MARCH 31, 2021 AND 2020

(in thousands, except shares)

(Unaudited)

FOR THE NINE MONTHS ENDED MARCH 31, 2021:

Common Stock

Additional

Accumulated

Treasury Stock

Total Stockholders'

Shares

Par Value

Paid-in-Capital

Deficit

Shares

Cost

Equity

Balance, July 1, 2020
29,680,843 $ 59 $ 50,263 $ (44,156 ) 34,900 $ (99 ) $ 6,067
Stock compensation expense for employee stock options
- - 8 - - - 8
Net income
- - - 1,041 - - 1,041
Balance, September 30, 2020
29,680,843 59 50,271 (43,115 ) 34,900 (99 ) 7,116
Stock compensation expense for employee stock options
- - 86 - - - 86
Shares issued upon exercise of employee stock options
35,000 - 7 - - - 7
Net income
- - - 1,224 - - 1,224
Balance, December 31, 2020
29,715,843 59 50,364 (41,891 ) 34,900 (99 ) 8,433
Stock compensation expense for employee stock options
- - 68 - - - 68
Shares issued upon exercise of employee stock options
66,700 1 6 - - - 7
Net income
- - - 1,241 - - 1,241
Balance, March 31, 2021
29,782,543 $ 60 $ 50,438 $ (40,650 ) 34,900 $ (99 ) $ 9,749

FOR THE NINE MONTHS ENDED MARCH 31, 2020:

Common Stock

Additional

Accumulated

Treasury Stock

Total Stockholders'

Shares

Par Value

Paid-in-Capital

Deficit

Shares

Cost

Equity

Balance, July 1, 2019
29,600,843 $ 59 $ 50,197 $ (48,264 ) 34,900 $ (99 ) $ 1,893
Stock compensation expense for employee stock options
- - 15 - - - 15
Net income
- - - 312 - - 312
Balance, September 30, 2019
29,600,843 59 50,212 (47,952 ) 34,900 (99 ) 2,220
Stock compensation expense for employee stock options
- - 15 - - - 15
Net income
- - - 959 - - 959
Balance, December 31, 2019
29,600,843 59 50,227 (46,993 ) 34,900 (99 ) 3,194
Stock compensation expense for employee stock options
- - 14 - - - 14
Net income
- - - 936 - - 936
Balance, March 31, 2020
29,600,843 $ 59 $ 50,241 $ (46,057 ) 34,900 $ (99 ) $ 4,144

See accompanying notes to condensed consolidated financial statements.

-4-

INTEGRATED BIOPHARMA, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands, except share and per share amounts)

(Unaudited)

Six months ended

December 31,

2020

2019

Cash flows provided by operating activities:

Net income
$ 2,265 $ 1,271
Adjustments to reconcile net income to net cash from operating activities:

Depreciation and amortization
170 160
Amortization of operating lease right-of-use assets
241 233
Stock based compensation
94 30
Change in deferred tax assets
26 (43 )
Realized gain on sale of investment in iBio Stock
(56 ) -
Unrealized loss on investment in iBio Stock
73 55
Other, Net
19 7
Changes in operating assets and liabilities:

Decrease (increase) in:

Accounts receivable
970 (441 )
Inventories
(3,815 ) (471 )
Other current assets
(240 ) (10 )
Security deposits and other assets
(25 ) 24
(Decrease) increase in:

Accounts payable
1,758 403
Accrued expenses and other liabilities
(74 ) 73
Operating lease obligations
(242 ) (233 )
Net cash provided by operating activities
1,164 1,058

Cash flows from investing activities:

Purchase of property and equipment
(117 ) (101 )
Proceeds from sale of iBio Stock
96 -
Proceeds from sale of machinery and equipment
- 3
Net cash used in investing activities
(21 ) (98 )

Cash flows from financing activities:

Advances under revolving credit facility
28,579 23,826
Proceeds from exercise of employee stock options
7 -
Repayments of advances under revolving credit facility
(29,151 ) (24,469 )
Repayments under term note payables
(862 ) (610 )
Repayments under finance lease obligations
(75 ) (115 )
Net cash used in financing activities
(1,502 ) (1,368 )

Net decrease in cash
(359 ) (408 )
Cash at beginning of period
402 475
Cash at end of period
$ 43 $ 67

INTEGRATED BIOPHARMA, INC. AND SUBSIDIARIES					INTEGRATED BIOPHARMA, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS					CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
*(in thousands, except share and per share amounts)*					*(in thousands, except share and per share amounts)*
(Unaudited)					(Unaudited)

						Nine months ended
						March 31,
						2021			2020
Cash flows provided by operating activities:
Net income						$	3,506		$	2,207
Adjustments to reconcile net income to net cash from operating activities:
Depreciation and amortization							253			239
Amortization of operating lease right-of-use assets							364			341
Stock based compensation							162			44
Change in deferred tax assets							421			(101	)
Realized gain on sale of investment in iBio Stock							(56	)		(49	)
Unrealized loss (gain) on investment in iBio Stock							51			(35	)
Other, Net							16			11
Changes in operating assets and liabilities:
Decrease (increase) in:
Accounts receivable							(948	)		166
Inventories							(3,321	)		(1,247	)
Other assets							(158	)		(11	)
(Decrease) increase in:
Accounts payable							2,201			2,256
Accrued expenses and other liabilities							212			71
Operating lease obligations							(365	)		(343	)
Net cash provided by operating activities							2,338			3,549

Cash flows from investing activities:
Purchase of property and equipment							(150	)		(158	)
Proceeds from sale of iBio Stock							96			85
Proceeds from sale of machinery and equipment							-			3
Net cash used in investing activities							(54	)		(70	)

Cash flows from financing activities:
Advances under revolving credit facility							41,758			35,190
Proceeds from exercise of employee stock options							14			-
Repayments of advances under revolving credit facility							(43,288	)		(37,599	)
Repayments under term note payables							(990	)		(823	)
Repayments under finance lease obligations							(75	)		(157	)
Net cash used in financing activities							(2,581	)		(3,389	)

Net (decrease) increase in cash							(297	)		90
Cash at beginning of period							402			475
Cash at end of period						$	105		$	565

Supplemental disclosures of cash flow information:
Interest paid	$	123	$	228		$	176		$	323
Income taxes paid	$	258	$	155		$	408		$	303

Supplemental disclosures of non-cash flow transactions:
Amount owed on purchase of property and equipment	$	32	$	-		$	50		$	-

See accompanying notes to condensed consolidated financial statements.

-5-

INTEGRATED BIOPHARMA, INC. AND ITS SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

~~(in~~(in thousands, except share and per share amounts)

(Unaudited)

Note 1. Principles of Consolidation and Basis of Presentation

Basis of Presentation of Interim Financial Statements

The accompanying condensed consolidated financial statements for the interim periods are unaudited and include the accounts of Integrated BioPharma, Inc., a Delaware corporation (together with its subsidiaries, the “Company”). The interim condensed consolidated financial statements have been prepared in conformity with Rule 8-03 of Regulation S-X of the Securities and Exchange Commission (“SEC”) and therefore do not include information or footnotes necessary for a complete presentation of financial position, results of operations and cash flows in conformity with accounting principles generally accepted in the United States of ~~America.~~America ("GAAP"). However, all adjustments (consisting only of normal recurring adjustments) which are, in the opinion of management, necessary for a fair presentation of the financial position and operating results for the periods presented have been included. These condensed consolidated financial statements should be read in conjunction with the financial statements and notes thereto, together with Management’s Discussion and Analysis of Financial Condition and Results of Operations, contained in the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2020 (“Form 10-K”), as filed with the SEC. The June 30, 2020 balance sheet was derived from audited financial statements, but does not include all disclosures required by ~~accounting principles generally accepted in the United States of America.~~GAAP. The preparation of the unaudited condensed financial statements in conformity with these accounting principles requires management to make estimates and assumptions that affect the amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the period. Ultimate results could differ from the estimates of management. The results of operations for the three and ~~six~~nine months ended ~~December~~March 31, ~~2020~~2021 are not necessarily indicative of the results for the full fiscal year ending June 30, 2021 or for any other period.

Nature of Operations

The Company is engaged primarily in manufacturing, distributing, marketing and sales of vitamins, nutritional supplements and herbal products. The Company’s customers are located primarily in the United States, Luxembourg and Canada. The Company was previously known as Integrated Health Technologies, Inc. and, prior to that, as Chem International, Inc. The Company was reincorporated in its current form in Delaware in 1995. The Company continues to do business as Chem International, Inc. with certain of its customers and certain vendors.

The Company’s business segments include: (a) Contract Manufacturing operated by Manhattan Drug Company, Inc. (“MDC”), which manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers and specialized health-care providers and (b) Other Nutraceutical Businesses which includes the operations of (i) AgroLabs, Inc. (“AgroLabs”), which distributes healthful nutritional products for sale through major mass market, grocery and drug and vitamin retailers, under the following brands: Peaceful Sleep, Wheatgrass and other products which are being introduced into the market (these are referred to as our branded products), (ii) The Vitamin Factory (the “Vitamin Factory”), which sells private label MDC products, as well as our AgroLabs products, through the Internet, (iii) IHT Health Products, Inc. (“IHT”) a distributor of fine natural botanicals, including multi minerals produced under a license agreement, (iv) MDC Warehousing and Distribution, Inc., a service provider for warehousing and fulfillment services and (v) Chem International, Inc. (“Chem”), a distributor of certain raw materials for DSM Nutritional Products LLC.

Accounting Policies

Reclassifications. Certain prior year amounts have been reclassified to conform to the current year presentation.

-6-

INTEGRATED BIOPHARMA, INC. AND ITS SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

~~(in~~(in thousands, except share and per share amounts)

(Unaudited)

Accounting Pronouncements Recently Adopted

On August 28, 2018, the Financial Accounting Standards Board (“FASB”) issued ASU 2018-13, Fair Value Measurement: Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement (Topic 820), which changes the fair value measurement disclosure requirements of ASC 820. This ASU removes certain disclosure requirements regarding the amounts and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy and the policy for timing of transfers between the levels. This ASU also adds disclosure requirements regarding unrealized gains and losses included in Other Comprehensive Income for recurring Level 3 fair value measurements and the range and weighted average of unobservable inputs used in Level 3 fair value measurements. ASU 2018-13 is effective for the fiscal year beginning July 1, 2020, including interim periods therein. Early adoption is permitted for any eliminated or modified disclosures upon issuance of ASU 2018-13. This new guidance did not have a material impact on the Company’s Condensed Consolidated Financial Statements.

Aside from the adoption of ASUs, as described above, there have been no material changes during fiscal year 2020 in the Company’s significant accounting policies to those previously disclosed in the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2020.

Significant Accounting Policies

Revenue Recognition. The Company recognizes product sales revenue, the prices of which are fixed and determinable, when title and risk of loss have transferred to the customer, when estimated provisions for product returns, rebates, charge-backs and other sales allowances are reasonably determinable, and when collectability is reasonably assured. Accruals for these items are presented in the consolidated financial statements as reductions to sales. The Company’s net sales represent gross sales invoiced to customers, less certain related charges for discounts, returns, rebates, charge-backs and other allowances. Cost of sales includes the cost of raw materials and all labor and overhead associated with the manufacturing and packaging of the products. Gross margins are affected by, among other things, changes in the relative sales mix among our products and valuation and/or charge off of slow moving, expired or obsolete inventories. To perform revenue recognition for arrangements within the scope of ASC 606, the Company performs the following five steps:

●

● identification of the promised goods or services in the contract;

●

determination of whether the promised goods or serves are performance obligations including whether they are distinct in the context of the contract;

●

measurement of the transaction price, including the constraint on variable consideration;

●

allocation of the transaction price to the performance obligations based on estimated selling prices; and

●

recognition of revenue when (or as) the Company satisfies each performance obligation. A performance obligation is a promise to transfer a distinct good or service to the customer and is the unit of account in ASC 606.

~~● determination of whether the promised goods or serves are performance obligations including whether they are distinct in the context of the contract;~~

~~● measurement of the transaction price, including the constraint on variable consideration;~~

~~● allocation of the transaction price to the performance obligations based on estimated selling prices; and~~

● recognition of revenue when (or as) the Company satisfies each performance obligation. A performance obligation is a promise to transfer a distinct good or service to the customer and is the unit of account in ASC 606.

Leases. We determine if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (“ROU”) assets, other current liabilities, and operating lease liabilities on our consolidated balance sheets. Finance leases are included in property and equipment, current portion of long term debt, and long-term debt obligation on our consolidated statement of financial condition.

Operating lease ROU assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of future payments.

~~-7-~~

~~INTEGRATED BIOPHARMA, INC. AND ITS SUBSIDIARIES~~

~~NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS~~

~~(in thousands, except share and per share amounts)~~

~~(Unaudited)~~

The operating lease ROU asset also includes any lease payments made and excludes lease incentives and initial direct costs incurred. Our lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term.

-7-

INTEGRATED BIOPHARMA, INC. AND ITS SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except share and per share amounts)

(Unaudited)

We have lease agreements with lease and non-lease components, which are generally accounted for separately. For certain equipment leases, such as vehicles, we account for the lease and non-lease components as a single lease component.

Earnings Per Share. Basic earnings per common share amounts are based on weighted average number of common shares outstanding. Diluted earnings per share amounts are based on the weighted average number of common shares outstanding, plus the incremental shares that would have been outstanding upon the assumed exercise of all potentially dilutive stock options, subject to anti-dilution limitations using the treasury stock method.

The following potentially dilutive shares for stock options were not included in the computation of weighted average diluted common shares outstanding as the effect of doing so would be anti-dilutive for the three and ~~six~~nine months ended ~~December~~March 31, ~~2020~~2021 and ~~2019:~~2020:

	Three Months Ended				Six Months Ended				Three Months Ended				Nine Months Ended
	December 31,				December 31,				March 31,				March 31,
	2020		2019		2020		2019		2021		2020		2021		2020

Anti-dilutive stock options		770,000		50,000		770,000		50,000		-		-		150,000		-
Total anti-dilutive shares		770,000		50,000		770,000		50,000		-		-		150,000		-

Note 2. Inventories

Inventories are stated at the lower of cost or net realizable value using the first-in, first-out method and consist of the following:

	December 31,		June 30,		March 31,		June 30,
	2020		2020		2021		2020

Raw materials	$	9,528	$	6,610	$	9,786	$	6,610
Work-in-process		2,996		2,612		2,270		2,612
Finished goods		1,392		879		1,366		879
Total	$	13,916	$	10,101	$	13,422	$	10,101

-8-

INTEGRATED BIOPHARMA, INC. AND ITS SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

~~(in~~(in thousands, except share and per share amounts)

(Unaudited)

Note 3. Property and Equipment, net

Property and equipment, net consists of the following:

December 31,

June 30,

2020

2020

Land and building
$ 1,250 $ 1,250
Leasehold improvements
1,358 1,287
Machinery and equipment
6,490 6,465
Transportation equipment
6 6
9,104 9,008
Less: Accumulated depreciation and amortization
(7,453 ) (7,312 )
Total
$ 1,651 $ 1,696

March 31,

June 30,

2021

2020

Land and building
$ 1,250 $ 1,250
Leasehold improvements
1,316 1,287
Machinery and equipment
6,324 6,465
Transportation equipment
6 6
8,896 9,008
Less: Accumulated depreciation and amortization
(7,259 ) (7,312 )
Total
$ 1,637 $ 1,696

Depreciation and amortization expense recorded on property and equipment was ~~$87~~$83 and ~~$69~~$79 for the three months and ~~$170~~$253 and ~~$160~~$239 for ~~six~~the nine months ended ~~December~~March 31, ~~2020~~2021 and ~~2019,~~2020, respectively. Additionally, the Company disposed of fully depreciated property of ~~$17~~$216 and $6 in the ~~six~~nine months ended ~~December~~March 31, 2021 and 2020, ~~and 2019, respectively and~~respectively. Additionally, the Company recognized a ~~loss~~net gain on ~~disposal~~disposals of $8$10 on property in the aggregate amount of ~~$20~~$100 that ~~was~~were not fully depreciated and a gain on the sale of equipment of $3 in the ~~six~~nine months ended ~~December~~March 31, ~~2020~~2021 and ~~2019,~~2020, respectively.

Note 4. Senior Credit Facility and other Long Term Debt

As of ~~December~~March 31, ~~2020~~2021 and June 30, 2020, the Company had the following debt outstanding:

	Principal Amount						Interest Rate			Maturity Date	Principal Amount						Interest Rate			Maturity Date
	As of December 31, 2020			As of June 30, 2020							As of March 31, 2021			As of June 30, 2020

Revolving advances under Senior Credit Facility with PNC Bank, National Association	$	3,475		$	4,046			3.25	%	5/15/2024
Installment Note with PNC Bank, National Association		1,722			2,584			3.50	%	5/15/2024
Payroll Protection Program Loan with PNC Bank, National Association		1,639			1,639			1.00	%	4/30/2022
Revolving advances under Senior Credit
Facility with PNC Bank, National Association											$	2,516		$	4,046			3.25	%	5/15/2024
Installment Note with PNC Bank												1,594			2,584			3.50	%	5/15/2024
Payroll Protection Program Loan with PNC Bank												1,639			1,639			1.00	%	4/30/2022
Capitalized lease obligations		-			75			4.01% -9.38	%	12/1/2020		-			75			4.01% - 9.38	%	12/1/2020
Total outstanding debt		6,836			8,344							5,749			8,344
Less: Revolving Advances		(3,475	)		(4,046	)						(2,516	)		(4,046	)
Prepaid financing costs		(35	)		(39	)						(22	)		(39	)
Current portion of long term debt, net		(2,856	)		(2,823	)						(3,171	)		(2,823	)
Long term debt, net	$	470		$	1,436						$	40		$	1,436

SENIOR CREDIT FACILITY

On May 15, 2019, the Company, MDC, AgroLabs, IHT, IHT Properties Corp. (“IHT Properties”) and Vitamin Factory (collectively, the “Borrowers”) amended the Revolving Credit, Term Loan and Security Agreement (the “Amended Loan Agreement”) with PNC Bank, National Association as agent and lender (“PNC”) and the other lenders party thereto entered into on June 27, 2012, as amended on February 19, 2016, and May 15, 2019.

-9-

INTEGRATED BIOPHARMA, INC. AND ITS SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

~~(in~~(in thousands, except share and per share amounts)

(Unaudited)

The Amended Loan Agreement provides for a total of $11,585 in senior secured financing (the “Senior Credit Facility”) as follows: (i) discretionary advances (“Revolving Advances”) based on eligible accounts receivable and eligible inventory in the maximum amount of $8,000 (the “Revolving Credit Facility”), and (ii) a term loan in the amount of $3,585 (the “Term Loan”). The Senior Credit Facility is secured by all assets of the Borrowers, including, without limitation, machinery and equipment, real estate owned by IHT Properties, and common stock of iBio, Inc. (“iBio Stock”) owned by the Company. Revolving Advances bear interest at PNC’s Base Rate (3.25% as of ~~December~~March 31, ~~2020~~2021 and June 30, 2020) or the Eurodollar Rate, at Borrowers’ option, plus 2.50%. The Term Loan bears interest at PNC’s Base Rate (3.50% as of ~~December~~March 31, ~~2020~~2021 and June 30, 2020) or the Eurodollar Rate at Borrowers’ option, plus 3.00%.

Upon and after the occurrence of any event of default under the Amended Loan Agreement, and during the continuation thereof, interest shall be payable at the interest rate then applicable plus 2%. The Senior Credit Facility matures on May 15, 2024 (the “Senior Maturity Date”).

The principal balance of the Revolving Advances is payable on the Senior Maturity Date, subject to acceleration, based upon a material adverse event clause, as defined, subjective accelerations for borrowing base reserves, as defined or upon the occurrence of any event of default under the Amended Loan Agreement or earlier termination of the Amended Loan Agreement pursuant to the terms thereof. The Term Loan shall be repaid in eighty-four (84) consecutive monthly installments of principal, the first eighty-three (83) of which shall be in the amount of $43, commencing on the first business day of June, 2019, and continuing on the first business day of each month thereafter, with a final payment of any unpaid balance of principal and interest payable on the Senior Maturity Date. The foregoing is subject to customary mandatory prepayment provisions and acceleration upon the occurrence of any event of default under the Amended Loan Agreement or earlier termination of the Amended Loan Agreement pursuant to the terms thereof.

The Revolving Advances are subject to the terms and conditions set forth in the Amended Loan Agreement and are made in aggregate amounts at any time equal to the lesser of (x) $8,000 or (y) an amount equal to the sum of: (i) up to 85%, subject to the provisions in the Amended Loan Agreement, of eligible accounts receivables (“Receivables Advance Rate”), plus (ii) up to the lesser of (A) 75%, subject to the provisions in the Amended Loan Agreement, of the value of the eligible inventory (“Inventory Advance Rate” and together with the Receivables Advance Rate, collectively, the “Advance Rates”), (B) 85% of the appraised net orderly liquidation value of eligible inventory (as evidenced by the most recent inventory appraisal reasonably satisfactory to PNC in its sole discretion exercised in good faith) and (C) the inventory sublimit in the aggregate at any one time (“Inventory Advance Rate” and together with the Receivables Advance Rate, collectively, the “Advance Rates”), minus (iii) the aggregate Maximum Undrawn Amount of all outstanding Letters of Credit, minus (iv) such reserves as PNC may reasonably deem proper and necessary from time to time.

The Amended Loan Agreement contains customary mandatory prepayment provisions, including, without limitation the requirement to use any sales proceeds from the sale of iBio Stock to repay the Term Loan and to prepay the outstanding amount of the Term Note in an amount equal to twenty-five percent (25%) of Excess Cash Flow (as defined in the Amended Loan Agreement) for each fiscal year commencing with the fiscal year ended June 30, 2016, payable upon delivery of the financial statements to PNC referred to in and required by the Amended Loan Agreement for such fiscal year but in any event not later than one hundred twenty (120) days after the end of each such fiscal year, which amount shall be applied ratably to the outstanding principal installments of the Term Loan in the inverse order of the maturities thereof.

-10-

INTEGRATED BIOPHARMA, INC. AND ITS SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except share and per share amounts)

(Unaudited)

The Amended Loan Agreement also contains customary representations and warranties, covenants and events of default, including, without limitation, (i) a fixed charge coverage ratio maintenance requirement and (ii) an event of default tied to any change of control as defined in the Amended Loan Agreement. As of ~~December~~March 31, ~~2020,~~2021, the Company was in compliance with the fixed charge coverage ratio maintenance requirement and with the required annual payments of 25% of the Excess Cash Flow for each fiscal year commencing with the fiscal year ended June 30, 2016 and used the proceeds of $96 from the sale of iBio Stock in the ~~six~~nine months ended ~~December~~March 31, ~~2020~~2021 to repay the Term Loan.

~~-10-~~

~~INTEGRATED BIOPHARMA, INC. AND ITS SUBSIDIARIES~~

~~NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS~~

~~(in thousands, except share and per share amounts)~~

~~(Unaudited)~~

In connection with the Senior Credit Facility, the following loan documents were executed: (i) a Stock Pledge Agreement with PNC, pursuant to which the Company pledged to PNC the iBio Stock; (ii) a Mortgage and Security Agreement with PNC with IHT Properties; and (iii) an Environmental Indemnity Agreement with PNC.

OTHER LONG TERM DEBT

Paycheck Protection Program Term Note. On April 29, 2020, the Company entered into a Paycheck Protection Program Term Note (the “PPP Note”) with PNC in the amount of $1,639. The PPP Note has an interest rate of 1% and a maturity date of April 30, 2022. The PPP Note was issued by PNC to the Company pursuant to the Coronavirus, Aid, Relief, and Economic Security Act’s (the “CARES Act”) (P.L. 116-136) Paycheck Protection Program (the “Program”). Under the Program, all or a portion of the PPP Note may be forgiven in accordance with the Program requirements. On August 20, 2020, the PPP Note was amended to conform to the provisions under the Paycheck Protection Program Flexibility Act of 2020 (the “Flexibility Act”), which was signed into law on June 5, 2020. The Flexibility Act significantly modified the loan forgiveness process and provided other benefits to the PPP loan recipient. The amount of the forgiveness shall be calculated (and may be reduced) in accordance with the requirements of the Program, including the provisions of Section 1106 of the Cares Act and the Flexibility Act. No more than 40% of the amount forgiven can be attributable to non-payroll costs, as defined in the Program. There are no payments of interest or principal amortization due under the PPP Note while the PPP Note is in the Deferral Period, which is the period beginning on the date of the PPP Note, April 29, 2020, and ending on the Deferral Expiration Date. The Deferral Expiration Date is the date any forgiven amount is remitted to PNC or the date that a final determination is made that no portion of the PPP Note will be forgiven.

The Company applied for loan forgiveness on January 7, 2021. PNC has 60 days to review the application and submit to the Small Business Administration (the “SBA”) the determination based on the Company’s application. On January 29, 2021, the Company was notified that as a result of recent guidance and technical changes made by the SBA contained in a January 19, 2021 Interim Final Rule, the Procedural Notice on Over-Funded Loan Amounts and the Procedural Notice on the Re-Submission of Forgiveness Applications, PNC has temporarily paused the forgiveness application process for all 2020 first-draw PPP loans. Consequently, the 60-day review period for PNC to review and issue a decision to the SBA has been paused. PNC will resume the review process once the updated technical guidance is received by the SBA and their systems updated accordingly. The Company reapplied for loan forgiveness on April 7, 2021. As of ~~February 12,~~May 13, 2021, the Company has not received any determination from PNC. Any amounts not forgiven under the Program will be payable in equal installments of principal plus any interest owed on the payment date from the Deferral Expiration Date through the Maturity Date. Additionally, any accrued interest that is not forgiven under the Program will be due on the First Payment Date, which is the 15th of the month following the month in which the Deferral Expiration Date occurs.

If the Company fails to make timely payments under the PPP Note, PNC will charge the Company a late payment fee equal to the lesser of 5% of the amount of such payment or $100. In the event of Default, as defined in the PPP Note, the default rate of interest will 5% in excess of the interest rate in effect from time to time under the PPP Note.

-11-

INTEGRATED BIOPHARMA, INC. AND ITS SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except share and per share amounts)

(Unaudited)

Capitalized Lease Obligations. On December 1, 2020, the capitalized lease obligation entered into by the Company on February 1, 2019 with First American Equipment Finance in the amount of $233, which lease was secured by certain machinery and equipment, was satisfied with all payments being made under the capitalized lease obligation. The monthly lease payment was approximately $10 and had an imputed interest rate of 7.28%.

On December 1, 2020, the capitalized lease obligation entered into by the Company on December 8, 2015 with Wells Fargo Equipment Finance, Manufacturer Services Group in the amount of $129, which lease was secured by certain machinery and equipment, was satisfied with all payments being made under the capitalized lease obligation. The monthly lease payment was approximately $2 and had an imputed interest rate of 4.01%.

~~-11-~~

~~INTEGRATED BIOPHARMA, INC. AND ITS SUBSIDIARIES~~

~~NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS~~

~~(in thousands, except share and per share amounts)~~

~~(Unaudited)~~

Note 5. Significant Risks and Uncertainties

(a) Major Customers. In the three months ended ~~December~~March 31, ~~2020~~2021 and ~~2019,~~2020, approximately 92% and ~~93%~~91%, respectively, of consolidated net sales were derived from two customers. These two customers are in the Company’s Contract Manufacturing Segment and represented approximately ~~72%~~70% and 24% and ~~70%~~64% and 26% in the three months ended ~~December~~March 31, ~~2020~~2021 and ~~2019,~~2020, respectively. In each of the ~~six~~nine months ended ~~December~~March 31, ~~2020~~2021 and ~~2019,~~2020, approximately 92% of consolidated net sales were derived from the same two customers and net sales to these two customers represented approximately 70% and 24% in the ~~six~~nine months ended ~~December~~March 31, ~~2020~~2021 and ~~68%~~67% and 27% of net sales in the ~~six~~nine months ended ~~December~~March 31, ~~2019,~~2020, respectively. Accounts receivable from these two major customers represented approximately ~~88%~~89% and 92% of total net accounts receivable as of ~~December~~March 31, 2021 and June 30, 2020, respectively. The loss of any of these customers could have an adverse effect on the Company’s operations. Major customers are those customers who account for more than 10% of net sales.

(b) Other Business Risks. Approximately 71% of the Company’s employees are covered by a union contract and are employed in its New Jersey facilities. The contract was renewed on September 1, 2018 and will expire on August 31, 2022.

The COVID-19, or coronavirus, outbreak has the potential to cause a disruption in the Company’s supply chain. Currently, some of our suppliers of certain materials used in the production of our supplements are located in China and other impacted countries or other states within the United States. Most of these materials may be obtained from more than one supplier. However, due to port closures and other restrictions resulting from the coronavirus outbreak throughout the world, these suppliers, located both inside and outside of the United States, may have limited supply of the materials, which has caused prices of some materials to increase. These and other disruptions would likely impact the Company’s sales and operating results. If the Company is unable to obtain the necessary materials to produce a supplement within the Company’s standard lead times, it may delay the production and shipment of those supplements, thereby shifting the timing of recognizing the resulting sale to the Company’s customers. In addition, the significant outbreak of this contagious disease in the human population has resulted in a widespread health crisis that could adversely affect the economies and financial markets of many countries, resulting in an economic downturn that could affect demand for the Company’s products and impact the Company’s operating results.

The Company does not currently anticipate any negative impact to its margins resulting from the coronavirus outbreak, however; if the Company is unable to obtain the necessary materials to produce a supplement within its standard lead times or the necessary safety and cleaning supplies it may delay the production and shipment of those supplements to its customers, thereby shifting the timing of recognizing the resulting sale to its customers.

Note 6. Leases and other Commitments and Contingencies

(a) Leases. The Company has operating and finance leases for its corporate and sales offices, warehousing and packaging facilities and certain machinery and equipment, including office equipment. The Company’s leases have remaining terms of less than 1 year to approximately 5 years.

-12-

INTEGRATED BIOPHARMA, INC. AND ITS SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

~~(in~~(in thousands, except share and per share amounts)

(Unaudited)

The components of lease expense for the three months ended ~~December~~March 31, ~~2020~~2021 and ~~2019,~~2020, were as follows:

	Three months ended December 31,												Three months ended March 31,
	2020						2019						2021						2020
	Related Party - Vitamin Realty		Other Leases		Totals		Related Party - Vitamin Realty		Other Leases		Totals		Related Party - Vitamin Realty		Other Leases		Totals		Related Party - Vitamin Realty		Other Leases		Totals

Operating lease costs	$	141	$	25	$	166	$	142	$	25	$	167	$	141	$	24	$	165	$	142	$	24	$	166

Finance Operating Lease Costs:
Amortization of right-of use assets	$	-	$	12	$	12	$	-	$	2	$	2	$	-	$	-	$	-	$	-	$	14	$	14
Interest on operating lease liabilities		-		1		1		-		3		3		-		-		-		-		3		3
Total finance lease cost	$	-	$	13	$	13	$	-	$	5	$	5	$	-	$	-	$	-	$	-	$	17	$	17

The components of lease expense for the ~~six~~nine months ended ~~December~~March 31, ~~2020~~2021 and ~~2019,~~2020, were as follows:

	Six months ended December 31,												Nine months ended March 31,
	2020						2019						2021						2020
	Related Party - Vitamin Realty		Other Leases		Totals		Related Party - Vitamin Realty		Other Leases		Totals		Related Party - Vitamin Realty		Other Leases		Totals		Related Party - Vitamin Realty		Other Leases		Totals

Operating lease costs	$	283	$	49	$	332	$	283	$	56	$	339	$	424	$	73	$	497	$	425	$	80	$	505

Finance Operating Lease Costs:
Amortization of right-of use assets	$	-	$	24	$	24	$	-	$	29	$	29	$	-	$	24	$	24	$	-	$	43	$	43
Interest on operating lease liabilities		-		2		2		-		8		8		-		2		2		-		11		11
Total finance lease cost	$	-	$	26	$	26	$	-	$	37	$	37	$	-	$	26	$	26	$	-	$	54	$	54

Operating Lease Liabilities

Related Party Operating Lease Liabilities. Warehouse and office facilities are leased from Vitamin Realty Associates, LLC (“Vitamin Realty”), which is 100% owned by the Company’s chairman, and a major stockholder and certain of his family members, who are the Co-Chief Executive Officers and directors of the Company. On January 5, 2012, MDC entered into a second amendment of lease (the “Second Lease Amendment”) with Vitamin Realty for its office and warehouse space in New Jersey increasing its rentable square footage from an aggregate of 74,898 square feet to 76,161 square feet and extending the expiration date to January 31, 2026. This Second Lease Amendment provides for minimum annual rental payments of $533, plus increases in real estate taxes and building operating expenses. On May 19, 2014, AgroLabs entered into an amendment to the lease agreement entered into on January 5, 2012, with Vitamin Realty for an additional 2,700 square feet of warehouse space in New Jersey, the term of which was to expire on January 31, 2019 to extend the expiration date to June 1, 2024. This additional lease provides for minimum lease payments of $27 with annual increases plus the proportionate share of operating expenses.

-13-

INTEGRATED BIOPHARMA, INC. AND ITS SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except share and per share amounts)

(Unaudited)

Rent expense and lease amortization costs for the three months ended ~~December~~March 31, ~~2020~~2021 and ~~2019~~2020 on these leases were $221 and ~~$220,~~$216, respectively and ~~$443~~$664 and ~~$431~~$647 for the ~~six~~nine month periods ended ~~December~~March 31, ~~2020~~2021 and ~~2019,~~2020, respectively and are included in cost of sales and selling and administrative expenses in the accompanying Condensed Consolidated Statements of Operations. As of ~~December~~March 31, ~~2020~~2021 and June 30, 2020, the Company had outstanding current obligations to Vitamin Realty of ~~$64~~$71 and $62, respectively, included in accounts payable in the accompanying Condensed Consolidated Balance Sheet. Additionally, the Company has operating lease obligations of ~~$2,562~~$2,445 and $2,794 with Vitamin Realty as noted in the accompany Condensed Consolidated Balance Sheet as of ~~December~~March 31, ~~2020~~2021 and June 30, 2020, respectively.

~~-13-~~

~~INTEGRATED BIOPHARMA, INC. AND ITS SUBSIDIARIES~~

~~NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS~~

~~(in thousands, except share and per share amounts)~~

~~(Unaudited)~~

Other Operating Lease Liabilities. The Company has entered into certain non-cancelable operating lease agreements expiring up through May, 2023, related to machinery and equipment and office equipment.

As of ~~December~~March 31, ~~2020,~~2021, the Company’s right-of-use assets, lease obligations and remaining cash commitment on these leases were as follows:

	Right-of-use Assets		Current Portion of Operating Lease Obligations		Operating Lease Obligations		Remaining Cash Commitment		Right-of-use Assets		Current Portion of Operating Lease Obligations		Operating Lease Obligations		Remaining Cash Commitment

Vitamin Realty Leases	$	2,557	$	476	$	2,086	$	2,820	$	2,440	$	480	$	1,965	$	2,679
Machinery and equipment leases		10		8		2		10		7		7		-		7
Office equipment leases		16		9		7		17		13		8		5		14
	$	2,583	$	493	$	2,095	$	2,847	$	2,460	$	495	$	1,970	$	2,700

As of June 30, 2020, the Company’s ROU assets, lease obligations and remaining cash commitment on these leases were as follows:

	Right-of-use Assets		Current Portion Operating Lease Obligations		Operating Lease Obligations		Remaining Cash Commitment

Vitamin Realty Leases	$	2,788	$	467	$	2,327	$	3,103
Machinery and equipment leases		28		20		8		29
Office equipment leases		8		1		7		9
	$	2,824	$	488	$	2,342	$	3,141

As of ~~December~~March 31, ~~2020~~2021 and June 30, 2020, the Company’s weighted average discount rate and remaining term on lease liabilities were approximately 3.75% and 3.75% and ~~4.9~~4.7 years and 5.4 years, respectively.

Supplemental cash flows information related to leases for the ~~six~~nine months ended ~~December~~March 31, ~~2020,~~2021, is as follows:

Related Party - Vitamin Realty

Other Leases

Totals

Cash paid for amounts included in the measurement of lease liabilities:

Operating cash flows from operating leases
$ 283 $ 48 $ 331
Operating cash flows from finance leases
- 2 2
Financing cash flows from finance lease obligations
- 75 75

Related Party - Vitamin Realty

Other Leases

Totals

Cash paid for amounts included in the measurement of lease liabilities:

Operating cash flows from operating leases
$ 424 $ 55 $ 479
Operating cash flows from finance leases
- 2 2
Financing cash flows from finance lease obligations
- 75 75

-14-

INTEGRATED BIOPHARMA, INC. AND ITS SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

~~(in~~(in thousands, except share and per share amounts)

(Unaudited)

Supplemental cash flows information related to leases for the ~~six~~nine months ended ~~December~~March 31, ~~2019,~~2020, is as follows:

	Related Party - Vitamin Realty		Other Leases		Totals		Related Party - Vitamin Realty		Other Leases		Totals

Cash paid for amounts included in the measurement of lease liabilities:

Operating cash flows from operating leases	$	283	$	47	$	330	$	424	$	75	$	499
Operating cash flows from finance leases		-		8		8		-		11		11
Financing cash flows from finance lease obligations		-		115		115		-		157		157

In the ~~six~~nine months ended ~~December~~March 31, ~~2020,~~2021, the Company renewed, for one year, an operating lease for office space with an annual commitment of $25. On April 29, 2021, the Company entered into a 5 year operating lease for office equipment with an annual commitment of $7.

Maturities of operating lease liabilities as of ~~December~~March 31, ~~2020~~2021 were as follows:

	Operating			Related Party						Operating			Related Party
Year ending	Lease			Operating Lease						Lease			Operating Lease
June 30,	Commitment			Commitment			Total			Commitment			Commitment			Total

2021, remaining	$	12		$	282		$	294		$	6		$	141		$	147
2022		10			565			575			10			565			575
2023		2			565			567			2			565			567
2024		2			565			567			2			563			565
2025		1			563			564			1			534			535
2026		-			280			280			-			311			311
Total minimum lease payments		27			2,820			2,847			21			2,679			2,700
Imputed interest		(1	)		(258	)		(259	)		(1	)		(234	)		(235	)
Total	$	26		$	2,562		$	2,588		$	20		$	2,445		$	2,465

Total rent expense, lease amortization costs and interest expense, including real estate taxes and maintenance charges, was approximately ~~$265~~$264 and ~~$262~~$257 and ~~$530~~$794 and ~~$526~~$783 for the three and ~~six~~nine months ended ~~December~~March 31, ~~2020~~2021 and ~~2019,~~2020, respectively. Rent and lease amortization is included in cost of sales, selling and administrative expenses in the accompanying Condensed Consolidated Statements of Income.

(b) Legal Proceedings.

The Company is subject, from time to time, to claims by third parties under various legal theories. The defense of such claims, or any adverse outcome relating to any such claims, could have a material adverse effect on the Company’s liquidity, financial condition and cash flows.

Note 7. Related Party Transactions

See Note 6(a). Leases for related party lease transactions.

-15-

INTEGRATED BIOPHARMA, INC. AND ITS SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

~~(in~~(in thousands, except share and per share amounts)

(Unaudited)

Note 8. Segment Information and Disaggregated Revenue

The basis for presenting segment results generally is consistent with overall Company reporting. The Company reports information about its operating segments in accordance with GAAP which establishes standards for reporting information about a company’s operating segments.

The Company has divided its operations into two reportable segments as follows: Contract Manufacturing, and Other Nutraceutical Businesses. International sales, concentrated primarily in Europe, for the three months ended ~~December~~March 31, 2021 and 2020 were $2,333 and ~~2019 were $1,750 and $2,319,~~$2,573, respectively and for the ~~six~~nine months ended ~~December~~March 31, 2021 and 2020 were $5,550 and ~~2019 were $3,217 and $4,345,~~$6,918, respectively.

Financial information relating to the three months ended ~~December~~March 31, ~~2020~~2021 and ~~2019~~2020 operations by business segment and disaggregated revenues was as follows:

		Sales, Net						Segment							Sales, Net						Segment
		U.S.		International				Gross				Capital			U.S.		International				Gross				Capital
		Customers		Customers		Total		Profit		Depreciation		Expenditures			Customers		Customers		Total		Profit		Depreciation		Expenditures
Contract Manufacturing	2020	$	12,168	$	1,704	$	13,872	$	2,069	$	86	$	64	2021	$	14,311	$	2,308	$	16,619	$	2,550	$	82	$	33
	2019		11,501		2,303		13,804		1,927		69		43	2020		10,775		2,558		13,333		1,772		78		49

Other Nutraceutical Businesses	2020		339		46		385		105		1		-	2021		428		25		453		111		1		-
	2019		377		16		393		99		-		-	2020		283		15		298		80		1		8

Total Company	2020		12,507		1,750		14,257		2,174		87		64	2021		14,739		2,333		17,072		2,661		83		33
	2019		11,878		2,319		14,197		2,026		69		43	2020		11,058		2,573		13,631		1,852		79		57

Financial information relating to the ~~six~~nine months ended ~~December~~March 31, ~~2020~~2021 and ~~2019~~2020 operations by business segment and disaggregated revenues was as follows:

		Sales, Net						Segment							Sales, Net						Segment
		U.S.		International				Gross				Capital			U.S.		International				Gross				Capital
		Customers		Customers		Total		Profit		Depreciation		Expenditures			Customers		Customers		Total		Profit		Depreciation		Expenditures
Contract Manufacturing	2020	$	25,492	$	3,166	$	28,658	$	4,325	$	168	$	114	2021	$	39,803	$	5,474	$	45,277	$	6,875	$	250	$	147
	2019		20,502		4,286		24,788		3,177		159		101	2020		31,277		6,844		38,121		4,949		237		150

Other Nutraceutical Businesses	2020		720		51		771		222		2		3	2021		1,148		76		1,224		333		3		3
	2019		756		59		815		248		1		-	2020		1,039		74		1,113		328		2		8

Total Company	2020		26,212		3,217		29,429		4,547		170		117	2021		40,951		5,550		46,501		7,208		253		150
	2019		21,258		4,345		25,603		3,425		160		101	2020		32,316		6,918		39,234		5,277		239		158

Total Assets as of

March 31,

June 30,

2021

2020

Contract Manufacturing
$ 23,248 $ 19,581
Other Nutraceutical Businesses
2,883 3,363

Total Company
$ 26,131 $ 22,944

Total Assets as of

December 31,

June 30,

2020

2020

Contract Manufacturing
$ 21,876 $ 19,581

Other Nutraceutical Businesses
3,387 3,363
Total Company
$ 25,263 $ 22,944

-16-

Item 2. ~~MANAGEMENT’S~~MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANICAL CONDITION AND RESULTS OF OPERATION (dollars in thousands)

Certain statements set forth under this caption constitute “forward-looking statements.” See “Disclosure Regarding Forward-Looking Statements” on page 1 of this Quarterly Report on Form 10-Q for additional factors relating to such statements. The following discussion should also be read in conjunction with the condensed consolidated financial statements of the Company and Notes thereto included herein and the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2020.

The Company is engaged primarily in the manufacturing, distributing, marketing and sales of vitamins, nutritional supplements and herbal products. The Company’s customers are located primarily in the United States, Luxembourg and Canada.

Business Outlook

Our future results of operations and the other forward-looking statements contained in this Quarterly Report on Form 10-Q, including this “Management’s Discussion and Analysis of Financial Condition and Results of Operation”, involve a number of risks and uncertainties—in particular, the statements regarding our goals and strategies, new product introductions, plans to cultivate new businesses, future economic conditions, revenue, pricing, gross margin and costs, competition, the tax rate, and potential legal proceedings. We are focusing our efforts to improve operational efficiency and reduce spending that may have an impact on expense levels and gross margin. In addition to the various important factors discussed above, a number of other important factors could cause actual results to differ significantly from our expectations. See the risks described in “Risk Factors” in the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, ~~2020.~~2020 and in Part II of this Quarterly Report on Form 10-Q.

For the ~~six~~nine months ended ~~December~~March 31, ~~2020,~~2021, our net sales from operations increased by ~~$3,826~~$7,267 to approximately ~~$29,429~~$46,501 from approximately ~~$25,603~~$39,234 in the ~~six~~nine months ended ~~December~~March 31, ~~2019.~~2020, an increase of 18.5%. Our net sales in the Contract Manufacturing Segment increased by ~~$3,870, offset by a decrease~~$7,156 and in our Other Nutraceuticals Segment ~~of $44.~~by $111. Net sales increased in our Contract Manufacturing Segment primarily due to increased sales volumes to Life Extension and Herbalife in the amount of ~~$3,306~~$6,152 and ~~$160,~~$559, respectively. For the ~~six~~nine months ended ~~December~~March 31, ~~2020,~~2021, we had operating income of approximately ~~$2,753,~~$4,472, an increase of approximately ~~$1,072~~$1,831 from operating income of approximately ~~$1,681~~$2,641 for the ~~six~~nine months ended ~~December~~March 31, ~~2019.~~2020. Our profit margins increased from approximately ~~13.4%~~13.5% of net sales in the ~~six~~nine months ended ~~December~~March 31, ~~2019~~2020 to approximately 15.5% of net sales in the ~~six~~nine months ended ~~December~~March 31, ~~2020,~~2021, primarily as a result of the increased sales in our Contract Manufacturing Segment of approximately ~~$3,870.~~$7,156. Our consolidated selling and administrative expenses increased by approximately ~~$50~~$100 or approximately ~~2.9%~~3.8% in the ~~six~~nine months ended ~~December~~March 31, ~~2020~~2021 compared to the ~~six~~nine months ended ~~December~~March 31, ~~2019.~~2020. Our employee stock compensation expense increased by ~~$64~~$118, insurance costs of $24 and we had an increase in expected losses on customer receivables of ~~$30,~~$22, offset in part, from decreases in professional fees of ~~$40~~$36 primarily from decreased legal fees, along with a decrease in travel and entertainment of ~~$37.~~$44.

Our revenue from our two significant customers in our Contract Manufacturing Segment is dependent on their demand within their respective distribution channels for the products we manufacture for them. As in any competitive market, our ability to match or beat other contract manufacturers pricing for the same items may also alter our outlook and the ability to maintain or increase revenues. We will continue to focus on our core businesses and push forward in maintaining our cost structure in line with our sales and expanding our customer base.

The COVID-19, or coronavirus outbreak, has the potential to cause a disruption in our supply chain. Currently, some of our suppliers of certain materials used in the production of our supplements are located in China and other impacted countries or other states within the United States. Most materials may be obtained from more than one supplier. However, due to port closures and other restrictions resulting from the coronavirus outbreak throughout the world, these suppliers, located both inside and outside of the United States, may have limited supply of such materials, which has caused prices of some materials to increase. As of ~~February 12,~~May 13, 2021, we have had delays, however; we have not experienced a significant disruption in the supply chain for our raw materials.

~~-17-~~

We have taken measures to secure some surplus stock and have informed our customers who may be affected of the potential price increase. In addition, the significant outbreak of this contagious disease in the human population has resulted in a widespread health crisis that could adversely affect the economies and financial markets of many countries, resulting in an economic downturn that could affect demand for our products and impact our operating results.

-17-

In addition to supply chain issues resulting from the COVID-19 pandemic, we are experiencing supply chain disruptions relating to fuel refinery and transportation issues as it pertains to the production of plastics. This is impacting the supply and demand of bottles and caps, key components in our Contract Manufacturing Segment. Transportation, in general, continues to be an issue in the delay of receiving materials and our ability to meet promised delivery dates to our customers in the Contract Manufacturing Segment.

While, as of ~~February 12,~~May 13, 2021, we haven’t experienced a major disruption in the supply chain for our manufactured products, we ~~have,~~did, however, ~~seen~~see a disruption in the supply chain for personal protection equipment (“PPE”) and cleaning supplies used in our manufacturing facilities in accordance with our standard operating procedures and the updated guidelines issued by the Centers for Disease Control and Prevention (the “CDC”) for personal safety. The U.S. Department of Labor Occupational Safety and Health Administration has adopted the CDC guidelines and as such we are required to provide the PPE for our employees to wear while working. When we ~~have obtained~~did obtain the out of stock items, such as face masks, gloves and other protective personal items, the cost of such items were substantially higher than the historical costs. ~~This may~~Due to increased volumes of sales, the increased costs of PPE did not impact our ~~future~~ gross margins. Additionally, if we are unable to obtain cleaning supplies in the future, we may have to temporarily close areas of production until the needed supplies are obtained.

We do not currently anticipate any negative impact to our margins resulting from the coronavirus outbreak or the supply chain disruptions relating to fuel refinery and transportation, however; if we are unable to obtain the necessary materials to produce and bottle a supplement within our standard lead times or the necessary PPE and cleaning supplies, it may delay the production and shipment of those supplements, thereby shifting the timing of recognizing the resulting sale to our customers. If there are increased shipping costs as a result of the fuel refinery and transportation issues that we are not able to pass along to our customers, it could have a negative impact on our margins.

While our facilities ~~remained~~did remain open during the State of New Jersey lockdown during the coronavirus outbreak as an essential business, there can be no assurances that we will continue to operate if the Governor of New Jersey should modify or issue new executive orders prohibiting our facilities to remain open.

Critical Accounting Policies and Estimates

There have been no changes to our critical accounting policies in the three ~~and six~~ months ended ~~December~~March 31, ~~2020,~~2021, except as disclosed in Note 1. Principles of Consolidation and Basis of Presentation of the Condensed Financial Statements of the Company contained in this Quarterly Report on Form 10-Q. Critical accounting policies and the significant estimates made in accordance with them are regularly discussed by management with our Audit Committee. Those policies are discussed under “Critical Accounting Policies” in our “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in Item 7 of our Annual Report on Form 10-K for the year ended June 30, 2020 and in Note 1. Principles of Consolidation and Basis of Presentation of the Condensed Financial Statements of the Company contained in this Quarterly Report on Form 10-Q.

-18-

Results of Operations (in thousands, except share and per share amounts)

Our results from operations in the following table, sets forth the income statement data of our results as a percentage of net sales for the periods indicated:

	For the three months						For the six months						For the three months						For the nine months
	ended December 31,						ended December 31,						ended March 31,						ended March 31,
	2020			2019			2020			2019			2021			2020			2021			2020

Sales, net		100.0	%		100.0	%		100.0	%		100.0	%		100.0	%		100.0	%		100.0	%		100.0	%

Costs and expenses:
Cost of sales		84.8	%		85.7	%		84.5	%		86.6	%		84.4	%		86.4	%		84.5	%		86.5	%
Selling and administrative		6.5	%		5.8	%		6.1	%		6.8	%		5.5	%		6.5	%		5.9	%		6.7	%
		91.3	%		91.5	%		90.6	%		93.4	%		89.9	%		92.9	%		90.4	%		93.2	%
Income from operations		8.7	%		8.5	%		9.4	%		6.6	%		10.1	%		7.1	%		9.6	%		6.8	%

Other income (expense), net
Interest expense		(0.6%	)		(0.8%	)		(0.5%	)		(0.9%	)		(0.3%	)		(0.7%	)		(0.5%	)		(0.8%	)
Realized gain on sale of iBio Stock		-			-			0.2	%		-			-			0.3	%		0.1	%		0.1	%
Unrealized loss on investments		(0.3%	)		(0.2%	)		(0.3%	)		(0.2%	)
Unrealized gain (loss) on investments														0.1	%		0.7	%		(0.1%	)		0.1	%
Other income, net		0.1	%		0.1	%		0.0	%		0.1	%		0.1	%		-			0.1	%		0.1	%
Other expense, net		(0.8%	)		(0.9%	)		(0.6%	)		(1.0%	)		(0.1%	)		0.3	%		(0.4%	)		(0.5%	)


Income before income taxes		7.9	%		7.6	%		8.8	%		5.6	%		10.0	%		7.4	%		9.2	%		6.3	%

Provision for income taxes		(0.7%	)		0.8	%		1.1	%		0.6	%		2.7	%		0.5	%		1.7	%		0.6	%

Net income		8.6	%		6.8	%		7.7	%		5.0	%		7.3	%		6.9	%		7.5	%		5.7	%

For the ~~Six~~nine months ended ~~December~~March 31, ~~2020~~2021 compared to the ~~Six~~nine months ended ~~December~~March 31, ~~2019~~2020

Sales, net. Sales, net, for the ~~six~~nine months ended ~~December~~March 31, 2021 and 2020 were $46,501 and ~~2019 were $29,429 and $25,603,~~$39,234, respectively, an increase of ~~14.9%~~18.5%, and were comprised of the following:

Six months ended

Dollar

Percentage

December 31,

Change

Change

2020

2019

2020 vs 2019

2020 vs 2019

(amounts in thousands)

Contract Manufacturing:

US Customers
$ 25,492 $ 20,502 $ 4,990 24.3 %
International Customers
3,166 4,286 (1,120 ) (26.1% )
Net sales, Contract Manufacturing
28,658 24,788 3,870 15.6 %

Other Nutraceuticals:

US Customers
720 756 (36 ) (4.8% )
International Customers
51 59 (8 ) (13.6% )
Net sales, Other Nutraceuticals
771 815 (44 ) (5.4% )
Total net sales
$ 29,429 $ 25,603 $ 3,826 14.9 %

Nine months ended
Dollar

Percentage

March 31,
Change

Change

2021
2020
2021 vs 2020

2021 vs 2020

(amounts in thousands)

Contract Manufacturing:

US Customers
$ 39,803 $ 31,277 $ 8,526 27.3 %
International Customers
5,474 6,844 (1,370 ) (20.0 %)
Net sales, Contract Manufacturing
45,277 38,121 7,156 18.8 %

Other Nutraceuticals:

US Customers
1,148 1,039 109 10.5 %
International Customers
76 74 2 2.7 %
Net sales, Other Nutraceuticals
1,224 1,113 111 10.0 %

Total net sales
$ 46,501 $ 39,234 $ 7,267 18.5 %

In each of the ~~six~~nine months ended ~~December~~March 31, ~~2020~~2021 and ~~2019,~~2020, a significant portion of our consolidated net sales, approximately 92%, were concentrated among two customers in our Contract Manufacturing Segment, Life Extension and Herbalife. Life Extension and Herbalife represented approximately 70% and 24% and ~~68%~~67% and 27%, respectively, of our Contract Manufacturing Segment’s net sales in the ~~six~~nine months ended ~~December~~March 31, ~~2020~~2021 and ~~2019,~~2020, respectively. Innophos (a customer of our Other Nutraceutical Businesses), while not a significant customer of our consolidated net sales, represented approximately 0% and ~~18%~~13% of the Other Nutraceutical Businesses net sales in the ~~six~~nine months ended ~~December~~March 31, ~~2020~~2021 and ~~2019,~~2020, respectively. The loss of any of these customers could have a significant adverse impact on our financial condition and results of operations.

-19-

The increase in net sales of approximately ~~$3,826~~$7,267 was primarily the result of increased net sales in our Contract Manufacturing Segment by ~~$3,870~~$7,156 primarily due to increased sales volumes to Life Extension and Herbalife in the amounts of ~~$3,306~~$6,152 and ~~$160,~~$559, respectively, and a combined net increase to our other customers of ~~$404.~~$445.

Cost of sales. Cost of sales increased by approximately ~~$2,704~~$5,336 to ~~$24,882~~$39,293 for the ~~six~~nine months ended ~~December~~March 31, ~~2020,~~2021, as compared to ~~$22,178~~$33,957 for the ~~six~~nine months ended ~~December~~March 31, ~~2019~~2020 or approximately ~~12%~~15.7%. Cost of sales decreased as a percentage of sales to 84.5% for the ~~six~~nine months ended ~~December~~March 31, ~~2020~~2021 as compared to ~~86.6%~~86.5% for the ~~six~~nine months ended ~~December~~March 31, ~~2019.~~2020. The increase ~~of 12.2%~~ in the cost of goods sold amount is consistent and expected with the ~~increased~~increase in net ~~sales of approximately 14.9%.~~sales. The decrease in the cost of goods sold as a percentage of net sales and the resulting increase in gross profit, was primarily the result of the increased net sales ~~used~~not needed to offset the fixed manufacturing overhead. ~~There were no significant changes in the cost of goods sold in our other two segments other than the variances in sales.~~

Selling and Administrative Expenses. There was an increase in selling and administrative expenses of ~~$50,~~$100, approximately 3%4% in the ~~six~~nine months ended ~~December~~March 31, ~~2020~~2021 as compared to the ~~six~~nine months ended ~~December~~March 31, ~~2019.~~2020. As a percentage of sales, net, selling and administrative expenses were approximately 6% and 7% in the ~~six~~nine months ended ~~December~~March 31, ~~2020~~2021 and ~~2019,~~2020, respectively. The increase of ~~$50~~$100 was primarily from increases in (i) employee stock compensation expense of ~~$64~~$118 as a result of issuing stock options in November 2020, with no such grant in the period ended ~~December~~March 31, ~~2019~~2020; (ii) increased insurance premium costs for general liability and directors and officers due to the general increases in the insurance market for potential COVID-19 related claims of $24 and; ~~(ii) an increase in~~(iii) expected losses on customer receivables of ~~$30.~~$22. These increases we offset, in part, by decreases in (i) professional and consulting fees of approximately ~~$40~~$36 primarily as the result of decreased legal fees of approximately ~~$52~~$42 from general legal counsel offset by an increase in of ~~$12~~$6 in other professional consulting services and (ii) travel and entertainment expenses of ~~$37~~$44 as the result of the travel and entertainment restrictions from the COVID-19 pandemic. All other operating expenses increased in aggregate amount of $17 in the nine months ended March 31, 2021 as compared to the nine months ended March 31, 2020.

Other income (expense), net. Other income (expense), net was approximately ~~$156~~$(169) for the ~~six~~nine months ended ~~December~~March 31, ~~2020~~2021 compared to ~~$261~~$(218) for the ~~six~~nine months ended ~~December~~March 31, ~~2019,~~2020, and was composed of:

Six months ended

Nine months ended

December 31,

March 31,

2020

2019

2021

2020

(dollars in thousands)

Other income (expense), net
(dollars in thousands)

Interest expense
$ (155 ) $ (233 ) $ (213 ) $ (329 )
Realized gain on sale of investment in iBio Stock
56 - 56 49
Unrealized loss on investment in iBio Stock
(73 ) (55 )
Unrealized (loss) gain on investment in iBio Stock
(51 ) 35
Other income
16 27 39 27
Other income (expense), net
$ (156 ) $ (261 ) $ (169 ) $ (218 )

Our interest expense for the ~~six~~nine months ended ~~December~~March 31, ~~2020~~2021 decreased by ~~$78~~$116 from the ~~six month~~nine-month period ended ~~December~~March 31, ~~2019,~~2020, primarily resulting from of lower average daily balances outstanding under the Senior Credit Facility with PNC and a decrease in the interest rates of approximately 1.5% in the ~~six~~nine months ended ~~December~~March 31, ~~2020~~2021 from the ~~six~~nine months ended ~~December~~March 31, ~~2019~~2020 (See Note 4 to the condensed consolidated financial statements included in this Quarterly Report on Form 10-Q).

In the ~~six~~nine months ended ~~December~~March 31, 2021 and 2020, we sold 16,000 shares of iBio Stock for a gain of $56 ~~with no such sales in the six months ended December 31, 2019.~~and 40,000 shares of iBio Stock for a gain of $49, respectively. Also, in the ~~six~~nine months ended ~~December~~March 31, ~~2020,~~2021, and ~~2019,~~2020, we had an unrealized loss on the remaining iBio Stock of approximately ~~$73~~$51 and ~~$55,~~an unrealized gain of $35, respectively.

-20-

Provision for income taxes. For the ~~six~~nine months ended ~~December~~March 31, ~~2020~~2021 and ~~2019,~~2020, we had a state income tax provision of approximately ~~$311~~$375 and ~~$158,~~$318, respectively and federal income tax expense of $422 in the nine months ended March 31, 2021 and a $102 federal income tax benefit ~~of $9~~ in the ~~six~~nine months ended ~~December 31, 2019, compared to a federal tax provision of $21 in the six months ended December~~March 31, 2020. We continue to maintain a reserve on a portion of our deferred tax assets as it has been determined that based upon past losses, the Company’s past liquidity concerns and the current economic environment, it is “more likely than not” that the Company’s deferred tax assets may not be fully realized.

Net income. Our net income for the ~~six~~nine months ended ~~December~~March 31, ~~2020~~2021 and ~~2019~~2020 was approximately ~~$2,265~~$3,506 and ~~$1,271,~~$2,207, respectively. The increase of approximately ~~$994~~$1,299 was primarily the result of increased operating income of ~~$1,072~~$1,831 and decreased interest expense of ~~$78,~~$116, offset by ~~increases~~an increase in ~~selling and administrative expenses of $50 and~~the provision for income taxes of ~~$183.~~$581.
For the Three Months Ended ~~December~~March 31, ~~2020~~2021 compared to the Three Months Ended ~~December~~March 31, ~~2019~~2020

Sales, net. Sales, net, for the three months ended ~~December~~March 31, 2021 and 2020 were $17,072 and ~~2019 were $14,257 and $14,197,~~$13,631, respectively, an increase of ~~0.4%~~25.2%, and are comprised of the following:

Three months ended

Dollar

Percentage

December 31,

Change

Change

2020

2019

2020 vs 2019

2020 vs 2019

(amounts in thousands)

Contract Manufacturing:

US Customers
$ 12,168 $ 11,501 $ 667 5.8 %
International Customers
1,704 2,303 (599 ) (26.0% )
Net sales, Contract Manufacturing
13,872 13,804 68 0.5 %

Other Nutraceuticals:

US Customers
339 377 (38 ) (10.1% )
International Customers
46 16 30 187.5 %
Net sales, Other Nutraceuticals
385 393 (8 ) (2.0% )
Total net sales
$ 14,257 $ 14,197 $ 60 0.4 %

Three months ended

Dollar

Percentage

March 31,

Change

Change

2021

2020

2021 vs 2020

2021 vs 2020

(amounts in thousands)

Contract Manufacturing:

US Customers
$ 14,311 $ 10,775 $ 3,536 32.8 %
International Customers
2,308 2,558 (250 ) (9.8% )
Net sales, Contract Manufacturing
16,619 13,333 3,286 24.6 %

Other Nutraceuticals:

US Customers
428 283 145 51.2 %
International Customers
25 15 10 66.7 %
Net sales, Other Nutraceuticals
453 298 155 52.0 %

Total net sales
$ 17,072 $ 13,631 $ 3,441 25.2 %

For the three months ended ~~December~~March 31, ~~2020~~2021 and ~~2019,~~2020, a significant portion of our consolidated net sales, approximately 92% and ~~93%~~91%, respectively, were concentrated among two customers, Life Extension and Herbalife, in our Contract Manufacturing Segment. Life Extension and Herbalife represented approximately ~~72%~~70% and 24% and ~~70%~~64% and 26%, respectively, of our Contract Manufacturing Segment’s net sales in the three months ended ~~December~~March 31, ~~2020~~2021 and 2019, respectively. Innophos, while not significant customer of our consolidated net sales, represented approximately 0% and 10%, of the Other Nutraceutical Businesses net sales in the three months ended December 31, 2020, ~~and 2019,~~ respectively. The loss of any of these customers could have a significant adverse impact on our financial condition and results of operations.

The increase in net sales of approximately ~~$60~~$3,441 was primarily the result of increased net sales in our Contract Manufacturing Segment by ~~$68~~$3,286 primarily due to increased sales volumes to Life Extension ~~of $313, offset by decreases in sales volume to~~and Herbalife in the ~~amount $369, respectively and a combined net increase to our other customers~~amounts of ~~$124.~~$2,846 an $399, respectively.

Cost of sales. Cost of sales ~~were substantially~~increased by approximately $2,632 to $14,411 for the ~~same in the each of~~ three months ended ~~December~~March 31, ~~2020 and 2019, $12,083~~2021, as compared to ~~$12,171, respectively.~~$11,779 for the three months ended March 31, 2020 or approximately 22.3%. Cost of sales decreased as a percentage of sales ~~was approximately 85%~~to 84.4% for ~~each of~~ the three months ended ~~December~~March 31, ~~2020~~2021 as compared to 86.4% for the three months ended March 31, 2020. The increase in the cost of goods sold amount is consistent and ~~2019.~~expected with the increase in net sales. The decrease in the cost of goods sold as a percentage of net sales and the resulting increase in gross profit, was primarily the result of the increased net sales not needed to offset the fixed manufacturing overhead.
-21-

Selling and Administrative Expenses. There was an increase in selling and administrative expenses of ~~$109,~~$50, approximately ~~13.3%~~5.6% in the three months ended ~~December~~March 31, ~~2020~~2021 as compared to the three months ended ~~December~~March 31, ~~2019.~~2020. As a percentage of sales, net, selling and administrative expenses were approximately ~~6.5%~~6% and ~~5.8%~~7% in the three months ended ~~December~~March 31, ~~2020~~2021 and ~~2019,~~2020, respectively. The increase of ~~$109~~$50 was primarily from ~~increases~~an increase in ~~(i)~~ employee stock compensation expense of ~~$71~~$54 as a result of issuing stock options in November 2020,
~~-21-~~
with no such grant in the period ended December 31, 2019 and; (ii) professional and consulting fees of approximately $31 primarily as the result of increased legal fees of approximately $9 from general legal counsel and of $22 in other professional consulting services. These increases were offset, in part by a decrease in travel and entertainment expenses of $22 as the result of the travel and entertainment restrictions from the COVID-19 pandemic.2019. No other component of selling and administrative expenses increased by more than ~~$10~~$14 in the ~~three month~~three-month period ended ~~December~~March 31, ~~2020~~2021 compared to the same period ended ~~December~~March 31, ~~2019.~~2020.

Other income (expense), net. Other income (expense), net was approximately ~~$115~~$(13) for the three months ended ~~December~~March 31, ~~2020~~2021 compared to ~~$134~~$43 for the three months ended ~~December~~March 31, ~~2019,~~2020, and is composed of:

Three months ended

Three months ended

December 31,

March 31,

2020

2019

2021

2020

(dollars in thousands)

Other income (expense), net
(dollars in thousands)

Interest expense
$ (79 ) $ (109 ) $ (58 ) $ (96 )
Unrealized loss on investment in iBio Stock
(44 ) (31 )
Realized gain on investment in iBio Stock
- 49
Unrealized gain on investment in iBio Stock
22 90
Other income
8 6 23 -
Other income (expense), net
$ (115 ) $ (134 ) $ (13 ) $ 43

Our interest expense for the three months ended ~~December~~March 31, ~~2020~~2021 decreased by ~~$30~~$38 from the ~~three month~~three-month period ended ~~December~~March 31, ~~2019,~~2020, primarily as the result of lower average daily balances outstanding under the Senior Credit Facility with ~~PNC and~~PNC.
In the three months ended March 31, 2020, we sold 40,000 shares of iBio Stock for a ~~decrease in the interest rates~~gain of ~~approximately 1.5%~~$49 with no such sales in the three ~~month period~~months ended ~~December~~March 31, 2021. Also, in the three months ended March 31, 2020, ~~from~~we had an unrealized gain on the remaining iBio Stock of approximately $90 compared to an unrealized gain of $22 in the three ~~month period~~months ended ~~December~~March 31, ~~2019 (See Note 4 to the condensed consolidated financial statements included in this Quarterly Report on Form 10-Q).~~2021.

Federal and state income tax expense, net. For the three months ended ~~December~~March 31, ~~2020 and 2019,~~2021, we had a federal deferred income tax expense of $401 and compared to a federal deferred income tax benefit of ~~$252 and $3, respectively,~~$93 in the three months ended March 31, 2020, and state income tax expense, net of approximately ~~$157~~$64 and ~~$115,~~$160, in the three months ended ~~December~~March 31, ~~2020~~2021 and ~~2019,~~2020, respectively. We continue to maintain a reserve on a portion of our deferred tax assets as it has been determined that based upon past losses, the Company’s past liquidity concerns and the current economic environment, it is “more likely than not” that the Company’s deferred tax assets may not be fully realized.

The decrease in state tax expense of approximately $96 is primarily the result the change in the state filing status from separate taxable entities in the State of New Jersey to an affiliated filing status. This status reduces the taxable state income due to taxable losses in some entities offsetting state taxable income in others.
The federal tax benefit of $93 in the three-month period ended March 31, 2020 includes the recognition of the change from the tax provision for the fiscal year ended June 30, 2019 to the tax return filed in March 2020 in the amount of $40 relating to the alternative minimum tax carryover due from payments made in prior years.
Net income. Our net income for the three months ended ~~December~~March 31, ~~2020~~2021 and ~~2019~~2020 was approximately ~~$1,224~~$1,241 and ~~$959,~~$936, respectively. The increase of approximately ~~$265~~$305 was primarily the result of the ~~decrease~~increase in operating income of $960 offset, in part, by the increase in the provision for income taxes of ~~$207.~~$398.
Seasonality
-22-

The nutraceutical business can be seasonal. Due to our current customer base in our contract manufacturing segment, our fiscal quarter ending December 31st each year tends to be more than our average quarterly volume for the other three fiscal quarters in the fiscal year. This increase is based on their forecast of their customer base.

The Company believes that there are non-seasonal factors that may influence the variability of quarterly results including, but not limited to, general economic and industry conditions that affect consumer spending, changing consumer demands and current news on nutritional supplements. Accordingly, a comparison of the Company’s results of operations from consecutive periods is not necessarily meaningful, and the Company’s results of operations for any period are not necessarily indicative of future periods.
~~-22-~~

Liquidity and Capital Resources

The following table sets forth, for the periods indicated, the Company’s net cash flows used in operating, investing and financing activities, its period end cash and cash equivalents and other operating measures:

For the six months ended

December 31,

2020

2019

(dollars in thousands)

Net cash provided by operating activities
$ 1,164 $ 1,058
Net cash used in investing activities
$ (21 ) $ (98 )
Net cash used in financing activities
$ (1,502 ) $ (1,368 )

Cash at end of period
$ 43 $ 67

For the nine months ended

March 31,

2021

2020

(dollars in thousands)

Net cash provided by operating activities
$ 2,338 $ 3,549
Net cash used in investing activities
$ (54 ) $ (70 )
Net cash used in financing activities
$ (2,581 ) $ (3,389 )

Cash at end of period
$ 105 $ 565

At ~~December~~March 31, ~~2020,~~2021, our working capital was approximately ~~$4,834,~~$6,154, an increase of ~~$1,472~~$2,792 from our working capital of $3,362 at June 30, 2020. Our current assets increased by ~~$2,638~~$4,065 offset by an increase in our current liabilities of ~~$1,166.~~$1,273. The increase in the current assets is primarily from increases in inventories in the amount of ~~$3,815 offset by a decrease in~~$3,321 and accounts receivable, net of ~~$970.~~$948.

Operating Activities

Net cash provided by operating activities of ~~$1,164~~$2,338 in the ~~six~~nine months ended ~~December~~March 31, ~~2020~~2021 includes net income of approximately ~~$2,265.~~$3,506. After excluding the effects of non-cash expenses, including depreciation and amortization, and changes in deferred tax assets, the adjusted cash provided from operations before the effect of the changes in working capital components was ~~$2,832.~~$4,717. Net cash provided by our operations in the ~~six~~nine months ended ~~December~~March 31, ~~2020~~2021 was offset by uses in our working capital assets and liabilities in the amount of approximately ~~$1,668~~$2,379 and was primarily the result of an ~~increase~~increases in our inventory of ~~$3,815,~~$3,321 and accounts receivable of $948, offset by an aggregate increase in accounts payable, accrued expenses and other liabilities of ~~$1,684 and a decrease in accounts receivable of $970.~~$2,413.

Net cash provided by operating activities of ~~$1,058~~$3,549 in the ~~six~~nine months ended ~~December~~March 31, ~~2019~~2020 includes net income of approximately ~~$1,271.~~$2,207. After excluding the effects of non-cash expenses, including depreciation and amortization, and changes in the fair value of derivative liabilities and deferred tax assets, the adjusted cash provided from operations before the effect of the changes in working capital components was ~~$1,746.~~$2,657. Net cash ~~used in~~provided by our operations in the ~~six~~nine months ended ~~December~~March 31, ~~2019~~2020 from our working capital assets and liabilities in the amount of approximately ~~$688~~$892 was primarily the result of cash ~~used~~provided by a decrease in accounts receivable of ~~$441~~$166 and ~~inventories of $471 and a decrease in obligations under operating leases of $234 offset by~~ an aggregate increase in accounts payable, accrued expenses and other liabilities of ~~$475.~~$2,327, offset, in part, by decreases in inventories of $1,247 and obligations under operating leases of $343.
Investing Activities

Cash used in investing activities in the ~~six~~nine months ended ~~December~~March 31, 2021 and 2020, of approximately ~~$21 was from proceeds of $96 from the sale of iBio Stock offset by the purchase of machinery~~$54 and ~~equipment of $117. Cash used in investing activities of $98 in the six months ended December 31, 2019~~$70, respectively, was used primarily for the purchase of machinery and equipment of ~~approximately $101.~~$150 and $158, respectively. Additionally, in the nine months ended March 31, 2021 and 2020, cash used in investing activities was offset, in part, with proceeds in the amount of $96 and $85 from the sale of 16,000 and 40,000 shares of iBio Stock, respectively.
-23-
Financing Activities

Cash used in financing activities was approximately ~~$1,502~~$2,581 for the ~~six~~nine months ended ~~December~~March 31, ~~2020,~~2021, and was primarily from repayments of advances under our revolving credit facility of ~~$29,151~~$43,288 and principal payments under our term notes in the amount of ~~$862,~~$990, offset by advances under our revolving credit facility of approximately ~~$28,579.~~$41,758.
~~-23-~~

Cash used in financing activities was approximately ~~$1,368~~$3,389 for the ~~six~~nine months ended ~~December~~March 31, ~~2019,~~2020, and was from repayments of advances under our revolving credit facility of ~~$24,469~~$37,599 and principal payments under our term notes and under capitalized lease obligations in the amount of ~~$610,~~$823 and $157, respectively, offset ~~in part,~~ by advances under our revolving credit facility of approximately ~~$23,826.~~$35,190.

As of ~~December~~March 31, ~~2020,~~2021, we had cash of ~~$43,~~$105, funds available under our revolving credit facility of approximately ~~$2,694~~$5,245 and working capital of approximately ~~$4,834.~~$6,154. Our working capital includes ~~$3,475~~$2,516 outstanding under our revolving line of credit which is not due until May 2024 but classified as current due to a subjective acceleration clause that could cause the advances to become currently due. (See Note 4 to the condensed consolidated financial statements included in this Quarterly Report on Form 10-Q). Additionally, we had income from operations of approximately ~~$2,753~~$4,472 in the ~~six~~nine months ended ~~December~~March 31, ~~2020.~~2021. After taking into consideration our interim results and current projections, management believes that operations, together with the revolving credit facility will support our working capital requirements at least through the period ending ~~February 12,~~May 13, 2022.

Our total annual commitments at ~~December~~March 31, ~~2020~~2021 for long term non-cancelable leases of approximately $565 consists of obligations under operating leases for facilities and operating lease agreements for the rental of warehouse equipment, office equipment and automobiles.

Capital Expenditures

The Company's capital expenditures for the ~~six~~nine months ended ~~December~~March 31, ~~2020~~2021 and ~~2019~~2020 were approximately ~~$117~~$150 and ~~$101,~~$158, respectively. The Company has budgeted approximately $475 for capital expenditures for fiscal year 2021. The total amount is expected to be funded from lease financing and cash provided from the Company’s operations.
Off-Balance Sheet Arrangements

The Company has no off-balance sheet arrangements.

Recent Accounting Pronouncements
None.

Impact of Inflation
The Company does not believe that inflation has significantly affected its results of operations.

Item 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Not applicable.
-24-

Item 4. CONTROLS AND PROCEDURES

Disclosure Controls and Procedures

Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed by the Company in the reports it files or submits under the Securities Exchange Act of 1934, as amended (the “Exchange Act”) is recorded, processed, summarized, and reported within the time periods specified by the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to provide reasonable assurance that information required to be disclosed by the Company in the reports it files or submits under the Exchange Act is accumulated and communicated to management, including the Co-Chief Executive Officers and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

~~-24-~~
Under the supervision and with the participation of management, including the Co-Chief Executive Officers and Chief Financial Officer, the Company has evaluated the effectiveness of its disclosure controls and procedures (as such term is defined in Rule 13a-15(e) and 15d-15(e) under the Exchange Act) as of ~~December~~March 31, ~~2020,~~2021, and, based upon this evaluation, the Co-Chief Executive Officers and Chief Financial Officer have concluded that these controls and procedures are effective in providing reasonable assurance of compliance.

Changes in Internal Control over Financial Reporting

No change in our internal control over financial reporting occurred during the three months ended ~~December~~March 31, ~~2020~~2021 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II – OTHER INFORMATION

Item 1. LEGAL PROCEEDINGS

From time to time, we may become involved in various lawsuits and legal proceedings that arise in the ordinary course of business. However, litigation is subject to inherent uncertainties and an adverse result in these or other matters may arise from time to time that may harm our business. We are currently not aware of any such legal proceedings or claims that we believe will have a material adverse effect on our business, financial condition or operating results.

Item 1A. Risk Factors

As of January 22, 2021, the ~~Company's~~Company’s common stock was ~~updated~~upgraded to the OTCQX® Best Market of the OTC Markets Group, Inc. and commenced quotation under the symbol ~~"INBP."~~“INBP.” In order to maintain quotation on the OTCQX, the Company will be required to comply with certain minimum qualitative and quantitative requirements, including with respect to corporate governance. There can be no assurances that the Company will be able to comply with these qualitative and quantitative requirements for continued quotation of its common stock on the OTCQX. If the Company ~~doesn't~~doesn’t maintain compliance with the OTCQX rules, the ~~Company's~~Company’s common stock may resume listing on the OTCQB and holders of the ~~Company's~~Company’s common stock may find it more difficult to sell their shares.

Item 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

Recent Sales of Unregistered Securities

None

-25-
Purchases of Equity Securities by the Issuer and Affiliated Purchasers
None

Item 3. DEFAULTS UPON SENIOR SECURITIES

None.

Item 4. MINE SAFETY DISCLOSURE

Not Applicable.
~~-25-~~

Item 5. OTHER INFORMATION

None.

Item 6. EXHIBITS

(a)Exhibits

Exhibit
Number
31.1
Certification of pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 by Co-Chief Executive Officers.
31.2
Certification of pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 by Chief Financial Officer.
32.1
Certification of periodic financial report pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 by Co-Chief Executive Officers.
32.2
Certification of periodic financial report pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 by Chief Financial Officer.
101
The following financial information from Integrated BioPharma, Inc.’s Quarterly Report on Form 10-Q for the quarter ended ~~December~~March 31, ~~2020,~~2021, formatted in XBRL (eXtensible Business Reporting Language): (i) Condensed Consolidated Statements of Income for the three and ~~six~~nine months ended ~~December~~March 31, ~~2020~~2021 and ~~2019,~~2020, (ii) Condensed Consolidated Balance Sheets as of ~~December~~March 31, ~~2020~~2021 and June 30, 2020, (iii) Condensed Consolidated Statement of Changes in Stockholders’ Equity for the ~~six~~nine months ended ~~December~~March 31, ~~2020~~2021 and ~~2019,~~2020, (iv) Condensed Consolidated Statements of Cash Flows for the ~~six~~nine months ended ~~December~~March 31, ~~2020~~2021 and ~~2019,~~2020, and (iv) the Notes to Condensed Consolidated Financial Statements.
-26-

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

INTEGRATED BIOPHARMA, INC.

Date:         ~~February 12,~~May 13, 2021 By: /s/ Christina Kay
Christina Kay,
Co-Chief Executive Officer

Date:         ~~February 12,~~May 13, 2021 By: ~~/s/~~/s/ Riva Sheppard
Riva Sheppard,
Co-Chief Executive Officer

Date:         ~~February 12,~~May 13, 2021 By: /s/ Dina L. Masi
Dina L. Masi,
Chief Financial Officer & Senior Vice President



~~-1-~~

-27-

Weighted average common shares outstanding - basic	29,658,661	29,565,943	29,652,302	29,565,943
Add: Equivalent shares outstanding	2,440,843	1,025,020	2,314,734	1,042,300
Weighted average common shares outstanding - diluted	32,099,504	30,590,963	31,967,036	30,608,243

INTEGRATED BIOPHARMA, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands, except for share and per share amounts)
(Unaudited)

	December 31,			June 30,
	2020			2020
Assets
Current Assets:
Cash	$	43		$	402
Accounts receivable, net		4,537			5,507
Inventories		13,916			10,101
Other current assets		603			451
Total current assets		19,099			16,461

Property and equipment, net		1,651			1,696
Operating lease right-of-use assets (includes $2,557 and $2,788 with a related party)		2,583			2,824
Deferred tax assets, net		1,857			1,883
Security deposits and other assets		73			80
Total Assets	$	25,263		$	22,944

Liabilities and Stockholders' Equity:
Current Liabilities:
Advances under revolving credit facility	$	3,475		$	4,046
Accounts payable (includes $64 and $62 due to related party)		6,132			4,358
Accrued expenses and other current liabilities		1,309			1,384
Current portion of long term debt, net		2,856			2,823
Current portion of operating lease liabilities (includes $476 and $467 with a related party)		493			488
Total current liabilities		14,265			13,099

Long term debt, net		470			1,436
Operating lease liabilities (includes $2,086 and $2,327 with a related party)		2,095			2,342
Total liabilities		16,830			16,877

Commitments and Contingencies

Stockholders' Equity :
Common Stock, $0.002 par value; 50,000,000 shares authorized;
29,715,843 and 29,680,843 shares issued and
29,680,943 and 29,645,943 shares outstanding, respectively		59			59
Additional paid-in capital		50,364			50,263
Accumulated deficit		(41,891	)		(44,156	)
Less: Treasury stock, at cost, 34,900 shares		(99	)		(99	)
Total Stockholders' Equity		8,433			6,067
Total Liabilities and Stockholders' Equity	$	25,263		$	22,944

Weighted average common shares outstanding - basic	29,709,992	29,565,943	29,671,251	29,565,943
Add: Equivalent shares outstanding	3,153,646	1,319,380	2,774,164	1,113,309
Weighted average common shares outstanding - diluted	32,863,638	30,885,323	32,445,415	30,679,252

INTEGRATED BIOPHARMA, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY
FOR THE SIX MONTHS ENDED DECEMBER 31, 2020 AND 2019
(in thousands, except shares)
(Unaudited)



FOR THE SIX MONTHS ENDED DECEMBER 31, 2020:
	Common Stock				Additional		Accumulated			Treasury Stock					Total Stockholders'
	Shares		Par Value		Paid-in-Capital		Deficit			Shares		Cost			Equity

Balance, July 1, 2020		29,680,843	$	59	$	50,263	$	(44,156	)		34,900	$	(99	)	$	6,067
Stock compensation expense for employee stock options		-		-		8		-			-		-			8
Net income		-		-		-		1,041			-		-			1,041
Balance, September 30, 2020		29,680,843		59		50,271		(43,115	)		34,900		(99	)		7,116
Stock compensation expense for employee stock options		-		-		86		-			-		-			86
Shares issued upon exercise of employee stock options		35,000		-		7		-			-		-			7
Net income		-		-		-		1,224			-		-			1,224
Balance, December 31, 2020		29,715,843	$	59	$	50,364	$	(41,891	)		34,900	$	(99	)	$	8,433

INTEGRATED BIOPHARMA, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY
FOR THE NINE MONTHS ENDED MARCH 31, 2021 AND 2020
(in thousands, except shares)
(Unaudited)



FOR THE NINE MONTHS ENDED MARCH 31, 2021:

	Common Stock				Additional		Accumulated			Treasury Stock					Total Stockholders'
	Shares		Par Value		Paid-in-Capital		Deficit			Shares		Cost			Equity

Balance, July 1, 2020		29,680,843	$	59	$	50,263	$	(44,156	)		34,900	$	(99	)	$	6,067
Stock compensation expense for employee stock options		-		-		8		-			-		-			8
Net income		-		-		-		1,041			-		-			1,041
Balance, September 30, 2020		29,680,843		59		50,271		(43,115	)		34,900		(99	)		7,116
Stock compensation expense for employee stock options		-		-		86		-			-		-			86
Shares issued upon exercise of employee stock options		35,000		-		7		-			-		-			7
Net income		-		-		-		1,224			-		-			1,224
Balance, December 31, 2020		29,715,843		59		50,364		(41,891	)		34,900		(99	)		8,433
Stock compensation expense for employee stock options		-		-		68		-			-		-			68
Shares issued upon exercise of employee stock options		66,700		1		6		-			-		-			7
Net income		-		-		-		1,241			-		-			1,241
Balance, March 31, 2021		29,782,543	$	60	$	50,438	$	(40,650	)		34,900	$	(99	)	$	9,749

	Total Assets as of
	March 31,		June 30,
	2021		2020
Contract Manufacturing	$	23,248	$	19,581
Other Nutraceutical Businesses		2,883		3,363

Total Company	$	26,131	$	22,944

	Six months ended				Dollar			Percentage
	December 31,				Change			Change
	2020		2019		2020 vs 2019			2020 vs 2019
	(amounts in thousands)
Contract Manufacturing:
US Customers	$	25,492	$	20,502	$	4,990			24.3	%
International Customers		3,166		4,286		(1,120	)		(26.1%	)
Net sales, Contract Manufacturing		28,658		24,788		3,870			15.6	%

Other Nutraceuticals:
US Customers		720		756		(36	)		(4.8%	)
International Customers		51		59		(8	)		(13.6%	)
Net sales, Other Nutraceuticals		771		815		(44	)		(5.4%	)
Total net sales	$	29,429	$	25,603	$	3,826			14.9	%

	For the six months ended
	December 31,
	2020			2019
	(dollars in thousands)

Net cash provided by operating activities	$	1,164		$	1,058
Net cash used in investing activities	$	(21	)	$	(98	)
Net cash used in financing activities	$	(1,502	)	$	(1,368	)

Cash at end of period	$	43		$	67

	For the nine months ended
	March 31,
	2021			2020
	(dollars in thousands)

Net cash provided by operating activities	$	2,338		$	3,549
Net cash used in investing activities	$	(54	)	$	(70	)
Net cash used in financing activities	$	(2,581	)	$	(3,389	)

Cash at end of period	$	105		$	565

31.1	Certification of pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 by Co-Chief Executive Officers.
31.2	Certification of pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 by Chief Financial Officer.
32.1	Certification of periodic financial report pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 by Co-Chief Executive Officers.
32.2	Certification of periodic financial report pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 by Chief Financial Officer.
101	The following financial information from Integrated BioPharma, Inc.’s Quarterly Report on Form 10-Q for the quarter ended ~~December~~March 31, ~~2020,~~2021, formatted in XBRL (eXtensible Business Reporting Language): (i) Condensed Consolidated Statements of Income for the three and ~~six~~nine months ended ~~December~~March 31, ~~2020~~2021 and ~~2019,~~2020, (ii) Condensed Consolidated Balance Sheets as of ~~December~~March 31, ~~2020~~2021 and June 30, 2020, (iii) Condensed Consolidated Statement of Changes in Stockholders’ Equity for the ~~six~~nine months ended ~~December~~March 31, ~~2020~~2021 and ~~2019,~~2020, (iv) Condensed Consolidated Statements of Cash Flows for the ~~six~~nine months ended ~~December~~March 31, ~~2020~~2021 and ~~2019,~~2020, and (iv) the Notes to Condensed Consolidated Financial Statements.

Date: ~~February 12,~~May 13, 2021	By: /s/ Christina Kay
	Christina Kay,
	Co-Chief Executive Officer

Date: ~~February 12,~~May 13, 2021	By: ~~/s/~~/s/ Riva Sheppard
	Riva Sheppard,
	Co-Chief Executive Officer

Date: ~~February 12,~~May 13, 2021	By: /s/ Dina L. Masi
	Dina L. Masi,
	Chief Financial Officer & Senior Vice President